Journal article
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients
Abstract
INTRODUCTION: Ipilimumab plus nivolumab was associated with a survival benefit in a phase III clinical trial of first-line treatment for metastatic renal cell carcinoma (mRCC). In this study, mRCC patients from the Canadian Kidney Cancer Information System (CKCis) database who received first-line ipilimumab plus nivolumab were analyzed to determine the safety and outcomes in a real-world setting.
PATIENTS AND METHODS: Patients who received …
Authors
Thana M; Basappa NS; Ghosh S; Kollmannsberger CK; Heng DYC; Hansen AR; Graham J; Soulières D; Reaume MN; Lalani A-KA
Journal
Clinical Genitourinary Cancer, Vol. 20, No. 3, pp. 210–218
Publisher
Elsevier
Publication Date
June 2022
DOI
10.1016/j.clgc.2021.12.003
ISSN
1558-7673